Stalemate for S&N, Kinetic patent row
This article was originally published in Clinica
Smith & Nephew's ongoing patent row with wound care rival Kinetic Concepts reached another milestone this week when the US Court of Appeals upheld a previous ruling that gave S&N the all-clear to market its gauze-based negative pressure wound therapy (NPWT) products. The court found that S&N's Versatile 1 system, which the company gained through its acquisition of BlueSky Medical, did not infringe Kinetic's Wake Forest patents. However, this favourable ruling for S&N was tempered by another verdict which stated that two of Kinetic's patents were valid and enforceable. Investors welcomed the court's affirmation of Kinetic's technology by boosting the San Antonio, California firm's stock value – Kinetic shares climbed 8% to close at $26.06 on February 2. The two companies are also embroiled in litigation relating to S&N's foam-based NPWT products. In January, the UK patent court banned S&N temporarily from selling these foam dressings in the UK until a trial date is set (see Clinica No 1332, p 19).
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.